NEW YORK, March 5 - Orchid BioSciences and First Genetic Trust on Tuesday said they plan to co-develop and market a range of pharmacogenetic services to the private sector, academia, and health-care providers.
The alliance hopes to provide researchers the tools to asses the correlates between genotypes and phenotypes. Specifically, it seeks to generate patient registries and support clinical trials, develop and validate assays, and provide genotyping services, bioinformatics, and data management.
FGT will bring it the partnership its genomic data-banking services, trial management, and patient registries to the alliance, while Orchid will offer its high throughput genotyping services and associated data support.
Financial terms of the agreement were not disclosed.
"As pharmacogenetics moves from the lab into clinical studies and the physician's office, we expect that our combined capabilities will help make possible the routine use of genomic data by medical researchers, manufacturers of therapeutics and diagnostics and health care providers," Jack T. Ball Jr., senior vice president and general manager of Orchid's Life Sciences unit, said in a statement.
Added Arthur Holden, chairman and CEO of FGT, the collaboration "should enable more rapid and efficient discovery, development and delivery of molecular assays and pharmacogenetic drugs."